Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362582783> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4362582783 endingPage "S477" @default.
- W4362582783 startingPage "S476" @default.
- W4362582783 abstract "IntroductionAllosensitization represents a barrier to successful heart transplant (HT). It increases waitlist (WL) mortality and may lead to inferior post-transplant outcomes. Strategies to reduce the number of circulating antibodies are utilized with little data on effectiveness of specific desensitization approaches in pediatric HT candidates. We present a case utilizing daratumumab, a monoclonal anti-CD38 antibody, for desensitization in a pediatric patient.Case ReportA 13 month old girl with large intracardiac fibroma was evaluated for HT and found to have significant complement fixing class II HLA antibodies (cPRA 99%) precluding HT. Based on the constellation of heart failure symptoms and expected WL time, decision was made to proceed to VAD support as a bridge to decision and facilitate desensitization. Initial desensitization therapy included plasmapheresis, rituximab, bortezomib, and IVIG, failed to reduce preformed class II HLA antibodies (cPRA remained 99%) and several class II antibodies remained C1q positive. Subsequent desensitization included rituximab, bortezomib and the addition of daratumumab. After receiving 6 doses of daratumumab, the repeat cPRA decreased to 57% with non-complement fixing antibodies present. Unfortunately, the patient experienced a significant GI bleed and required massive blood transfusion leading to rebound antibody development (figure 1). Once the patient was stable, daratumumab therapy was continued and her antibodies levels are presented in figure 1. Throughout desensitization the patient was maintained on IVIG, mycophenolate, and prednisolone. Daratumumab infusions were well tolerated with no major infectious complications. Now with a lower cPRA, she has increased chances for a successful HT.SummaryDesensitization therapy with daratumumab seems to be a safe and promising treatment option for highly sensitized pediatric patients in need for HT." @default.
- W4362582783 created "2023-04-06" @default.
- W4362582783 creator A5011878488 @default.
- W4362582783 creator A5012724711 @default.
- W4362582783 creator A5019353694 @default.
- W4362582783 creator A5019934977 @default.
- W4362582783 creator A5021720508 @default.
- W4362582783 creator A5058621681 @default.
- W4362582783 creator A5075163095 @default.
- W4362582783 creator A5077130026 @default.
- W4362582783 date "2023-04-01" @default.
- W4362582783 modified "2023-09-27" @default.
- W4362582783 title "(1108) New Desensitization Strategy: Daratumumab for Highly Sensitized Pediatric Heart Transplant Candidate" @default.
- W4362582783 doi "https://doi.org/10.1016/j.healun.2023.02.1319" @default.
- W4362582783 hasPublicationYear "2023" @default.
- W4362582783 type Work @default.
- W4362582783 citedByCount "1" @default.
- W4362582783 countsByYear W43625827832023 @default.
- W4362582783 crossrefType "journal-article" @default.
- W4362582783 hasAuthorship W4362582783A5011878488 @default.
- W4362582783 hasAuthorship W4362582783A5012724711 @default.
- W4362582783 hasAuthorship W4362582783A5019353694 @default.
- W4362582783 hasAuthorship W4362582783A5019934977 @default.
- W4362582783 hasAuthorship W4362582783A5021720508 @default.
- W4362582783 hasAuthorship W4362582783A5058621681 @default.
- W4362582783 hasAuthorship W4362582783A5075163095 @default.
- W4362582783 hasAuthorship W4362582783A5077130026 @default.
- W4362582783 hasBestOaLocation W43625827831 @default.
- W4362582783 hasConcept C126322002 @default.
- W4362582783 hasConcept C141071460 @default.
- W4362582783 hasConcept C159654299 @default.
- W4362582783 hasConcept C170493617 @default.
- W4362582783 hasConcept C203014093 @default.
- W4362582783 hasConcept C2776364478 @default.
- W4362582783 hasConcept C2777478702 @default.
- W4362582783 hasConcept C2778842783 @default.
- W4362582783 hasConcept C2779779143 @default.
- W4362582783 hasConcept C2780653079 @default.
- W4362582783 hasConcept C2781119759 @default.
- W4362582783 hasConcept C71924100 @default.
- W4362582783 hasConceptScore W4362582783C126322002 @default.
- W4362582783 hasConceptScore W4362582783C141071460 @default.
- W4362582783 hasConceptScore W4362582783C159654299 @default.
- W4362582783 hasConceptScore W4362582783C170493617 @default.
- W4362582783 hasConceptScore W4362582783C203014093 @default.
- W4362582783 hasConceptScore W4362582783C2776364478 @default.
- W4362582783 hasConceptScore W4362582783C2777478702 @default.
- W4362582783 hasConceptScore W4362582783C2778842783 @default.
- W4362582783 hasConceptScore W4362582783C2779779143 @default.
- W4362582783 hasConceptScore W4362582783C2780653079 @default.
- W4362582783 hasConceptScore W4362582783C2781119759 @default.
- W4362582783 hasConceptScore W4362582783C71924100 @default.
- W4362582783 hasIssue "4" @default.
- W4362582783 hasLocation W43625827831 @default.
- W4362582783 hasOpenAccess W4362582783 @default.
- W4362582783 hasPrimaryLocation W43625827831 @default.
- W4362582783 hasRelatedWork W2014021133 @default.
- W4362582783 hasRelatedWork W2143803333 @default.
- W4362582783 hasRelatedWork W2171070458 @default.
- W4362582783 hasRelatedWork W2525095138 @default.
- W4362582783 hasRelatedWork W2587983904 @default.
- W4362582783 hasRelatedWork W2758467670 @default.
- W4362582783 hasRelatedWork W2783888490 @default.
- W4362582783 hasRelatedWork W2794264828 @default.
- W4362582783 hasRelatedWork W3005443493 @default.
- W4362582783 hasRelatedWork W4296385710 @default.
- W4362582783 hasVolume "42" @default.
- W4362582783 isParatext "false" @default.
- W4362582783 isRetracted "false" @default.
- W4362582783 workType "article" @default.